Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK2 | P51955 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8811823 | 0.98 | NEK2 (0.36) | NEK2HSD17B10CRBN | |
| SCHEMBL23268287 | 0.82 | NEK2 (0.38) | NEK2HSD17B10CRBN | |
| SCHEMBL26271431 | 0.81 | CCNC (0.31) | — | |
| Hydrochloric Acid SCHEMBL7484202 | 0.79 | CCNC (0.30) | — | |
| SCHEMBL24090043 | 0.79 | PDE7A (0.32) | — | |
| SCHEMBL4842009 | 0.76 | — | — | |
| SCHEMBL2168757 | 0.76 | CCNC (0.32) | — | |
| SCHEMBL23009433 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL5941102 | 0.74 | — | — | |
| SCHEMBL10375357 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025076059-A1 | ROCAGLATE DERIVATIVES AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2025-04-10 | — | — | WO | claimed |
| US-9267122-B2 | Modulation of phospholipase D for the treatment of neurodegenerative disorders | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-02-23 | — | — | US | claimed |
| EP-1931680-A1 | INDOL-3-YL-CARBONYL-AZASPIRO DERIVATIVES AS VASOPRESSIN RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-18 | — | — | EP | claimed |
| WO-2007039438-A1 | INDOL-3-YL-CARBONYL-AZASPIRO DERIVATIVES AS VASOPRESSIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-12 | — | — | WO | claimed |
| EP-1569933-A1 | PYRROLIDINE AND AZETIDINE COMPOUNDS AS CCR5 ANTAGONISTS | SmithKline Beecham Corporation (US) | 2005-09-07 | — | — | EP | claimed |
| WO-2004055016-A1 | PYRROLIDINE AND AZETIDINE COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | claimed |
| US-12612395-B2 | Rocaglate derivatives and uses thereof | TRUSTEES OF BOSTON UNIVERSITY (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4584254-A1 | ISOQUINOLONES AS PI3K INHIBITORS | OnKure, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| WO-2025076059-A1 | ROCAGLATE DERIVATIVES AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20250115593-A1 | ROCAGLATE DERIVATIVES AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2025-04-10 | — | — | US | disclosed |
| WO-2025038395-A1 | BENZOPYRIDINONES AND BENZOPYRIMIDINONES AS PI3K INHIBITORS | ONKURE, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| US-20250034193-A1 | PHENOTHIAZINE DERIVATIVES AND USES THEREOF | CAMP4 THERAPEUTICS CORPORATION | 2025-01-30 | — | — | US | disclosed |
| US-12145963-B2 | Phenothiazine derivatives and uses thereof | CAMP4 THERAPEUTICS CORPORATION (US) | 2024-11-19 | — | — | US | disclosed |
| WO-1995022544-A2 | SUBSTITUTED 1,3,8-TRIAZA-SPIRO(4,5)-DECAN-4-ONE DERIVATIVES USEFUL AS PRELIMINARY STAGES IN THE PRODUCTION OF PHARMACEUTICALS | CIS BIO INTERNATIONAL (FR) | 1995-08-24 | — | — | WO | disclosed |
| EP-0594593-A1 | THERAPEUTICALLY USEFUL HETEROCYCLIC INDOLE COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 1994-05-04 | — | — | EP | disclosed |
| US-5302599-A | Administering for central nervous system and cardiovascular disorders | THE UPJOHN COMPANY (US) | 1994-04-12 | — | — | US | disclosed |
| EP-0539803-A1 | Triazospirodecanone-methyl-chromans for the treatment of central nervous system illnesses | BAYER AG (DE) | 1993-05-05 | — | — | EP | disclosed |
| WO-1991013872-A1 | THERAPEUTICALLY USEFUL HETEROCYCLIC INDOLE COMPOUNDS | THE UPJOHN COMPANY (US) | 1991-09-19 | — | — | WO | disclosed |
| US-4213963-A | Fluspirilene-containing compositions | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-07-22 | — | — | US | disclosed |
| US-4020072-A | PSYCHOTROPIC | E. R. SQUIBB & SONS, INC. (US) | 1977-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612395-B2 | Rocaglate derivatives and uses thereof | GLRB, SRR, HCAR3 | NEK2 3741/4885HSD17B10 162/4885CRBN 1060/4885 |
| US-20250115593-A1 | ROCAGLATE DERIVATIVES AND USES THEREOF | ACSL3, ADSL, ACSL6 | NEK2 4550/4885HSD17B10 357/4885CRBN 3641/4885 |
| US-12145963-B2 | Phenothiazine derivatives and uses thereof | RPLP2, RPS2, RPLP1 | NEK2 555/4885HSD17B10 3795/4885CRBN 458/4885 |
| US-20250034193-A1 | PHENOTHIAZINE DERIVATIVES AND USES THEREOF | RPLP2, RPS2, RPLP1 | NEK2 555/4885HSD17B10 3795/4885CRBN 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.